Key Segmentation
By Technology
-
Polymerase Chain Reaction
-
Next-Generation Sequencing
-
In Situ Hybridization
-
Immunohistochemistry
-
Others
By Product
-
Assay Kits & Reagents
-
Instruments
-
Others
By Cancer Type
-
Non-Small Cell Lung Cancer
-
Breast Cancer
-
Colorectal Cancer
-
Melanoma
-
Leukaemia
-
Others
By End User
-
Pharmaceutical & Biopharmaceutical Companies
-
Contract Research Organizations
-
Hospitals & Diagnostic Laboratories
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
The Oncology Companion Diagnostic Market is expected to grow at a CAGR of 11.09% from 2026 to 2035.
The Oncology Companion Diagnostic Market was valued at USD 5.09 Billion in 2025.
The Oncology Companion Diagnostic Market is driven by the rapid growth of targeted cancer therapies, increasing adoption of precision medicine, expanding use of NGS-based genomic profiling, and rising approval of liquid biopsy diagnostics for treatment selection.
The Non-Small Cell Lung Cancer segment dominated the Oncology Companion Diagnostic Market with approximately 31% share in 2025 through the broadest companion diagnostic-guided targeted therapy portfolio of any solid tumor type.
North America accounted for the leading revenue share of more than 42.86% in 2025.